NOACs compare favourably to warfarin in new studies

NOACs compare favourably to warfarin in new studies

June 22 2016 Two BMJ studies have further supported the use of alternatives to warfarin for...

Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

May 11 2016 Serious health risks in type 2 diabetes may be reduced more effectively with insulin...

Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

April 27 2016 Methotrexate in combination with sulphasalazine and hydroxychloroquine has been...

SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

April 20 2016 Patients taking sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin,...

Cochrane concludes daily iron supplements improves women’s overall activity

Cochrane concludes daily iron supplements improves women’s overall activity

April 20 2016 A Cochrane review has concluded that daily iron supplementation effectively reduces...

  • NOACs compare favourably to warfarin in new studies

    NOACs compare favourably to warfarin in new studies

    Wednesday, 22 June 2016 14:14
  • Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

    Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

    Wednesday, 11 May 2016 14:15
  • Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

    Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

    Wednesday, 27 April 2016 13:22
  • SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

    SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

    Wednesday, 20 April 2016 13:25
  • Cochrane concludes daily iron supplements improves women’s overall activity

    Cochrane concludes daily iron supplements improves women’s overall activity

    Wednesday, 20 April 2016 13:18

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

inhalerMarch 23 2016

While inhaled corticosteroids are known to increase the risk of pneumonia in chronic obstructive pulmonary disease, the benefits outweigh the risks, a review has concluded.

Conducted by the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC), the review also looked at whether there were any differences in the risk of pneumonia between products. It “did not find conclusive evidence of such difference. Pneumonia remains a common side effect for all of them,” said EMA.

“The Committee’s view is that the benefits of inhaled corticosteroids continue to outweigh their risks.” The committee has recommended that product information is now updated “to adequately reflect the current knowledge.”

EMA has said that the findings mean that there will be no change to the way these medicines should be used for the time being. However, it is calling on doctors and patients to be “vigilant for signs and symptoms of pneumonia in patients with COPD as the clinical features of pneumonia overlap with those of exacerbations of the underlying disease.”

Before the recommendation is adopted as the EMA’s final opinion, the PRAC recommendation will be considered by the Committee for Medicinal Products for Human Use (CHMP). “Further details including advice for patients and healthcare professionals will be published at the time of the CHMP opinion,” said EMA.

In a separate EMA announcement, the PRAC has issued advice for doctors and patients using the cancer medicine Zydelig (idelalisib). In particular, it has recommended that patients should receive antibiotics to prevent Pneumocystusjirovecii pneumonia developing. In addition, patients should also be monitored for infection and have regular blood tests for white blood cell counts.

Zydelig can be used in adults with chronic lymphocytic leukaemia (CLL) or who have follicular lymphoma (FL), a form of non-Hodgkin lymphoma.

Links:

EMA inhaled corticosteroids announcement

EMA Zydelig announcement

Clinical News

June 29 2016 The NHS should support clinical pharmacist roles in community pharmacies as well as at GP practices, the New NHS Alliance has proposed.
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...